Abstract
An analysis of the rising incidence and mortality rate of prostate cancer reveals the extraordinary importance of this disease in the world. Adenocarcinoma of the prostate is the most common cancer diagnosed in American males, reaching an estimated incidence of 32%, with 200,000 cases of newly diagnosed cancer cases expected in 1994.1 In addition, clinically inapparent prostate cancer is an extremely common finding. Over the age of 80, subclinical prostate cancer is found in approximately 60% of all men.2 Overall, it is estimated that there are 11 million men in the U.S. with lesions within their prostates that are histologically identifiable as cancer.3 Mortality from prostate cancer represents a considerable problem. It is expected that prostate cancer will account for 13% (38,000 cases) of male cancer deaths in 1994.1 This makes prostate cancer the second leading cause of cancer-related death in U.S. men after lung cancer. Mortality rates from prostate cancer appear to be on the rise. From 1970 to 1990 the age-adjusted mortality rate from prostate cancer increased approximately 7 % among U.S. caucasians. Since prostate cancer rates increase with age, as the longevity of the population increases, it is projected that prostate cancer will become the leading cause of cancer and cancer death in men. These observations demonstrate that prostate cancer is one of the major adverse factors in the health of the male population in the United States and for that matter, in the rest of the world as well.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
C.C. Boring, T.S. Squires, T. Tong, and S. Montgomery, Cancer statistics, 1994, CA Cancer J Clin. 44: 7 (1994).
J.M. Kozlowski, and J.T. Grayhack, Carcinoma of the prostate, in: Adult and Pediatric Urology, J. Y. Gillenwater, J. T. Grayhack, S. S. Howards and J. W. Duckett, eds. Mosby Year Book, St Louis (1991).
H. Carter, and D. Coffey: The magnitude of the problem in the United States., in: A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer., D. Coffey Resnick,M.,Dorr,F., et al., eds. Plenum Press, New York (1988).
L. Cannon, D. Bishop, M. Skolnick, S. Hunt, J. Lyon, and C. Smart, Genetic epidemiology of prostate cancer in the Utah Mormon genealogy., Cancer Survey. 1: 47 (1983).
C. Woolf, An investigation of the familial aspects of carcinoma of the prostate, Cancer. 13: 739 (1960).
W. Meikle, J. Smith, and D. West, Familial factors affecting prostatic cancer risk and plasma steroid levels, Prostate. 6: 121 (1985).
J.D. McConnell, Physiologic basis of endocrine therapy for prostatic cancer, Urol Clin North Amer. 18: 1 (1991).
P. Ekman, and J. Brolin, Steroid receptor profile in human prostate cancer metastases as compared with primary prostatic carcinoma, Prostate. 18: 147 (1991).
C. Huggins, R.E. Stevens, and C.V. Hodges, Studies on prostatic cancer.II. The effects of castration on advanced carcinoma of the prostate gland, Arch Surg. 43: 209 (1941).
R.M. Wolf, S.L. Schneider, J.E. Pontes, L. Englander, J.P. Karr, G.P. Murphy, and A.A. Sandberg, Estrogen and progestin receptors in human prostatic carcinoma, Cancer. 55: 2477 (1985).
G.G. Schwartz, and B.S. Hulka, Is Vitamin D deficiency a risk factor for prostate cancer?(Hypothesis), Anticancer Res. 10: 1307 (1990).
C.F. Garland, G.W. Comstock, F.C. Garland, K.J. Helsing, E.K. Shaw, and E.D. Gorham, Serum 25-Hydroxyvitamin D and colon cancer: Eight-year prospective study., Lancet. 2: 1176 (1989).
C.F. Garland, F.C. Garland, and E.D. Gorham, Can colon cancer incidence and death rates be reduced with calcium and vitamin D?, Am J Clin Nutr. 54 (Suppl.1): 193 (1991).
C.L. Hanchette, and G.G. Schwartz, Geographic patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation, Cancer. 70: 2861 (1992).
R.J. Skowronski, D.M. Peehl, and D. Feldman, Vitamin D and prostate cancer: 1,25 Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines, Endocrinology. 132: 1952 (1993).
R.J. Skowronski, D.M. Peehl, and D. Feldman, Actions of vitamin D3 analogs on human prostate cancer cell lines: Comparison with 1,25-dihydroxyvitamin D3, Endocrinology 136: 20 (1995).
D.M. Peehl, R.J. Skowronski, G.K. Leung, S.T. Wong, T.A. Stamey, and D. Feldman, Antiproliferative effects of 1,25-Dihydroxyvitamin D3 on primary cultures of human prostatic cells, Cancer Res. 54: 805 (1994).
D. Peehl, R.J. Skowronski, and D. Feldman, Role of vitamin D receptors in prostate cancer, in: Intl. Symp.“Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects, Elsevier, Amsterdam, in press (1994).
E.H. Corder, H.A. Guess, B.S. Hulka, G.D. Friedman, M. Sadler, R.T. Vollmer, B. Lobaugh, M.K. Drezner, J.h. Vogelman, and N. Orentreich, Vitamin D and prostate cancer: A prediagnostic study with stored sera, Cancer Epidemiology, Biomakers & Prevention. 2: 467 (1993).
A.W. Norman, J. Roth, and L. Orci, The vitamin D endocrine system: Steroid metabolism, hormone receptors, and biological response (calcium binding proteins)., Endocr Rev. 3: 331 (1982).
J.W. Pike, Vitamin D3 receptors: structure and function in transcription, Ann Rev Nutr. 11: 189 (1991).
R.M. Evans, The steroid and thyroid hormone receptor superfamily, Science. 240: 889 (1988).
B. O’Malley, The steroid receptor superfamily: more excitement predicted for the future, Mol Endocrinol. 4: 363 (1990).
D. Feldman, and P.J. Malloy, Hereditary 1,25 dihydroxyvitamin D resistant rickets: Molecular basis and implications for the role of 1,25(OH)2D3 in normal physiology, Mol Cell Endocrinol. 72: C57 (1990).
G.J. Miller, G.E. Stapleton, J.A. Ferrara, M.S. Lucia, S. Pfister, T.E. Hedlund, and P. Upadhya, The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1a,25-dihydroxyvitamin D3, Cancer Res. 52: 515 (1992).
K. Burton, A study of conditions and mechanisms of the diphenyl amine colorimetric estimation of deoxyribonucleic acid, Biochem J. 62: 315 (1956).
C. Auffray, and F. Rougeon, Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA., Eur JBiochem. 107: 303 (1980).
A.R. Baker, D.P. McDonnell, M. Hughes, T.M. Crisp, D.J. Mangelsdorf, M.R. Haussier, J.W. Pike, J. Shine, and B.W. O’Malley, Cloning and expression of full-length cDNA encoding human vitamin D receptor., Proc Natl Acad Sci USA. 85: 3294 (1988).
Y. Ohyama, M. Noshiro, and K. Okuda, Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24-hydroxylase, FEBSLett. 278: 195 (1991).
T.A. Stamey, H.C.B. Graves, N. Wenner, M. Ferrari, and F. Freiha, Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen, J Urol. 149: 787 (1993).
P.J. Malloy, Z. Hochberg, D. Tiosano, J.W. Pike, M.R. Hughes, and D. Feldman, The molecular basis of hereditary 1,25-dihydroxyvitamin D3 resistant rickets in seven related families, J Clin Invest. 86: 2071 (1990).
J.W. Pike, Monoclonal antibodies to chick intestinal receptors for 1,25-dihydroxyvitamin D3, J Biol Chem. 259: 1167 (1984).
T.A. Stamey, and J.N. Kabalin, Prostate specific antigen in the diagnosis and teratment of adenocarcinoma of the prostate.I.Untreated patients, J Urol. 141: 1070 (1989).
H.-P. Schmid, J.E. McNeal, and T.A. Stamey, Observations on the doubling time of prostate cancer, Cancer. 71: 2031 (1993).
M.A. Anzano, J.M. Smith, M.R. Uskokovic, C.W. Peer, L.T. Mullen, J.J. Letterio, M.C. Welsh, M.W. Shrader, D.1. Logsdon, C.L. Driver, C.C. Brown, A.R. Roberts, and M.B. Sporn, la,25-Dihydroxy-16ene-23yne-26,27-hexafluorocholecalciferol (Ro24–5531) a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat, Cancer Res. 54: 1653 (1994).
K.W. Colston, A.G. Mackay, S. Chander, L. Binderup, and R.C. Coombes, Novel vitamin D analogues suppress tumor growth in vivo, in: Vitamin D: Gene Regulation, Structure-Function Analysis and Clinical Application: Proceedings of the Eighth Workshop on Vitamin D, Berlin, de Gruyter, 465 (1991).
G. Schleicher, T.H. Privette, and W.E. Stumpf, Distribution of soltriol [1,25(OH)2-Vitamin D3] binding sites in male sex organs of the mouse: An autoradiographic study., J Histochem Cytochem. 37: 1083 (1989).
M.R. Walters, D.L. Cuneo, and A.P. and Jamison, A possible significance of new target tissues for 1,25-dihydroxyvitamin D3, J Steroid Biochem. 19: 913 (1983).
K. Colston, J.M. Colston, Fieldsteel, and D. Feldman, 1,25-Dihydroxyvitamin D3 receptors in human epithelial cancer cell lines, Cancer Res. 42: 856 (1982).
B.C. Osmundsen, H.F.S. Huang, M.B. Anderson, S. Christakos, and M.R. Walters, Multiple sites of action of the vitamin D endocrine system: FSH stimulation of testis 1,25-dihydroxyvitamin D3 receptors, J Steroid Biochem. 34: 339 (1989).
H. Reichel, H.P. Koeffler, and A.W. Norman, The role of the vitamin D endocrine system in health and disease, N Engl J Med. 320: 980 (1989).
W.E. Stumpf, M. Sar, F.A. Reid, and e. al., Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid, Science. 206: 1188 (1979).
E. Abe, C. Miyayra, H. Sakagami, M. Takeda, K. Konno, T. Yamazaki, S. Yoshiki, and T. Suda, Differentiation of mouse myeloid leukemia cells induced by la,25-dihydroxyvitamin D3., Proc NatlAcad Sci USA. 78: 4990 (1981).
K.W. Colston, U. Berger, and R.C. Coombes, Possible role for vitamin D in controlling breast cancer cell proliferation, Lancet. 1:188 (1989).
J.A. Eisman, D.H. Barkla, and P.J. Tutton, Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3, Cancer Res. 47: 21 (1987).
K. Colston, J.M. Colston, and D. Feldman, 1,25-Dihydroxyvitamin D3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture, Endocrinology. 108: 1083 (1981).
A. Brehier, and M. Thomassat, Human colon cell line HT-29: Characterisation of 1,25-dihydroxyvitamin D3 receptor and induction of differentiation by the hormone, J Steroid Biochem. 29: 265 (1988).
K.D. Harper, R.V. Iozzo, and J.G. Haddad, Receptors for and bioresponses to 1,25-dihydroxyvitamin D in a human colon carcinoma cell line (HT-29), Metabolism. 38: 1062 (1989).
X. Zhao, and D. Feldman, Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells, Endocrinology. 132: 1808 (1993).
P. Lointier, F. Meggouh, P. Dechelotte, D. Pezet, C. Ferrier, J. Chipponi, and S. Saez, 1,25-Dihydroxyvitamin D3 receptors and human colon adenocarcinoma, BrJSurg. 78: 435 (1991).
C.F. Garland, and F.C. Garland, Do vitamin D and sunlight reduce the likelihood of colon cancer?, Int J Epidemiol. 9: 227 (1980).
H.A.P. Pols, J.C. Birkenhager, J.A. Foekens, and J.P.T.M. Van Leeuwen, Vitamin D: A modulator of cell proliferation and differentiation, JSteroid Biochem. 37: 873 (1990).
T.A. Owen, M.S. Aronow, L.M. Barone, B. Bettencourt, G.S. Stein, and J.B. Lian, Pleitropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phehnotype: Dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in the normal rat osteoblast cultures, Endocrinology. 128: 1496 (1991).
E.M. Costa, H.M. Blau, and D. Feldman, 1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells, Endocrinology. 119: 2214 (1986).
S. Pillai, D.D. Bikle, and P.M. Elias, 1,25-dihydroxyvitamin D production and receptor binding in human keratinocytes varies with differentiation., JBiol Chem. 263: 5390 (1988).
T. Suda, T. Shinki, and N. Takahashi, The role of vitamin D in bone and intestinal cell differentiation, Ann Rev Nutr. 10: 195 (1990).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Feldman, D., Skowronski, R.J., Peehl, D.M. (1995). Vitamin D and Prostate Cancer. In: Diet and Cancer. Advances in Experimental Medicine and Biology, vol 354. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0949-7_5
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0949-7_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0951-0
Online ISBN: 978-1-4899-0949-7
eBook Packages: Springer Book Archive